The diagnostic yield of genetic and metabolic investigations in syndromic and nonsyndromic patients with autism spectrum disorder, global developmental delay, or intellectual disability from a dedicated neurodevelopmental disorders genetics clinic
- 20 June 2024
- journal article
- research article
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 194 (11) , e63791
Abstract
First‐tier genetic investigations for patients with neurodevelopmental disorders (NDDs) may include chromosomal microarray, Fragile X testing, and screening for inherited metabolic diseases, but most remain undiagnosed upon completion of testing. Here, we report the diagnostic yields of genetic testing for 537 patients with at least one of autism spectrum disorder, global developmental delay, and/or intellectual disability. Patients were assessed in a single neurodevelopmental genetics clinic, and each underwent a standardized history and physical examination. Each patient was characterized as syndromic or nonsyndromic based on clinical features. Our results demonstrate that multigene sequencing (with an NDD gene panel or exome) had a higher diagnostic yield (8%; 95% confidence interval [CI]: 5%, 13%) than chromosomal microarray and Fragile X testing combined (4%; 95% CI: 3%, 7%). Biochemical screening for inherited metabolic diseases had a diagnostic yield of zero. The diagnostic yield of genetic testing was significantly higher for syndromic patients than for nonsyndromic patients (odds ratio [OR] 3.09; 95% CI: 1.46, 6.83) and higher for female patients than for male (OR 3.21; 95% CI: 1.52, 6.82). These results add to the growing evidence supporting a comprehensive genetic evaluation that includes both copy number analysis and sequencing of known NDD genes for patients with NDDs.Keywords
This publication has 26 references indexed in Scilit:
- Genetic and metabolic investigations for individuals with neurodevelopmental disorders: A survey of Canadian geneticists' practicesAmerican Journal of Medical Genetics Part A, 2021
- Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disordersGenetics in Medicine, 2019
- The REDCap consortium: Building an international community of software platform partnersJournal of Biomedical Informatics, 2019
- The Heritability of Autism Spectrum DisorderJAMA, 2017
- Molecular Diagnostic Yield of Chromosomal Microarray Analysis and Whole-Exome Sequencing in Children With Autism Spectrum DisorderJAMA, 2015
- A Higher Mutational Burden in Females Supports a “Female Protective Model” in Neurodevelopmental DisordersThe American Journal of Human Genetics, 2014
- Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisionsGenetics in Medicine, 2013
- Consensus Statement: Chromosomal Microarray Is a First-Tier Clinical Diagnostic Test for Individuals with Developmental Disabilities or Congenital AnomaliesThe American Journal of Human Genetics, 2010
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Les standards de croissance de l’Organisation mondiale de la santé pour les nourrissons et les jeunes enfantsArchives de Pédiatrie, 2009